Cargando…

Therapies to Slow, Stop, or Reverse Parkinson’s Disease

Our understanding of PD pathophysiology is vastly improved compared to the situation 20 years ago. We have identified the major genetic risks for PD, we now have far more representative animal models of the disease, and we can be inspired by the early successes of others using Antisense Oligonucleot...

Descripción completa

Detalles Bibliográficos
Autores principales: Foltynie, Tom, Langston, J. William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311371/
https://www.ncbi.nlm.nih.gov/pubmed/30584162
http://dx.doi.org/10.3233/JPD-181481
_version_ 1783383604465762304
author Foltynie, Tom
Langston, J. William
author_facet Foltynie, Tom
Langston, J. William
author_sort Foltynie, Tom
collection PubMed
description Our understanding of PD pathophysiology is vastly improved compared to the situation 20 years ago. We have identified the major genetic risks for PD, we now have far more representative animal models of the disease, and we can be inspired by the early successes of others using Antisense Oligonucleotide and vaccination approaches in other neurodegenerative diseases. We also have a broad range of repurposed drugs showing the first signals of potential efficacy in the translational pipeline which are being driven forward through the various clinical trial stages. We believe we can be optimistic that the next 20 years will be a time for major breakthroughs towards the discovery of therapies that may slow, stop, or reverse PD.
format Online
Article
Text
id pubmed-6311371
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-63113712019-01-02 Therapies to Slow, Stop, or Reverse Parkinson’s Disease Foltynie, Tom Langston, J. William J Parkinsons Dis Review Our understanding of PD pathophysiology is vastly improved compared to the situation 20 years ago. We have identified the major genetic risks for PD, we now have far more representative animal models of the disease, and we can be inspired by the early successes of others using Antisense Oligonucleotide and vaccination approaches in other neurodegenerative diseases. We also have a broad range of repurposed drugs showing the first signals of potential efficacy in the translational pipeline which are being driven forward through the various clinical trial stages. We believe we can be optimistic that the next 20 years will be a time for major breakthroughs towards the discovery of therapies that may slow, stop, or reverse PD. IOS Press 2018-12-18 /pmc/articles/PMC6311371/ /pubmed/30584162 http://dx.doi.org/10.3233/JPD-181481 Text en © 2018 – IOS Press and the authors. All rights reserved https://creativecommons.org/licenses/by-nc/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Foltynie, Tom
Langston, J. William
Therapies to Slow, Stop, or Reverse Parkinson’s Disease
title Therapies to Slow, Stop, or Reverse Parkinson’s Disease
title_full Therapies to Slow, Stop, or Reverse Parkinson’s Disease
title_fullStr Therapies to Slow, Stop, or Reverse Parkinson’s Disease
title_full_unstemmed Therapies to Slow, Stop, or Reverse Parkinson’s Disease
title_short Therapies to Slow, Stop, or Reverse Parkinson’s Disease
title_sort therapies to slow, stop, or reverse parkinson’s disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6311371/
https://www.ncbi.nlm.nih.gov/pubmed/30584162
http://dx.doi.org/10.3233/JPD-181481
work_keys_str_mv AT foltynietom therapiestoslowstoporreverseparkinsonsdisease
AT langstonjwilliam therapiestoslowstoporreverseparkinsonsdisease